Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ana Ortiz-Guerrero

Nephrology Torrance, CA Medical Doctor

NPI 1275776536 CMS profile 714052

3291 Skypark Dr, Torrance, CA 90505

Open in the dashboard

General payments

$11,871

641 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ana Ortiz-Guerrero of Torrance, CA is reported in the CMS Open Payments database as having received $11,871 across 641 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,962 94
2024 General $2,728 149
2023 General $2,057 114
2022 General $1,975 107
2021 General $1,450 80
2020 General $977 55
2019 General $723 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ana Ortiz-Guerrero
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Ana Ortiz-Guerrero were reported at $1,962. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Ana Ortiz-Guerrero Nephrology median Middle half National median
2019 $723 $236 $90–$588 $163
2020 $977 $135 $46–$364 $114
2021 $1,450 $202 $67–$551 $132
2022 $1,975 $242 $77–$695 $149
2023 $2,057 $254 $84–$766 $160
2024 $2,728 $300 $99–$852 $164
2025 $1,962 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Relypsa, Inc. $1,069 57 payments
  2. Otsuka America Pharmaceutical, Inc. $1,010 47 payments
  3. Retrophin, Inc. $911 75 payments
  4. Novo Nordisk Inc $833 49 payments
  5. Amgen Inc. $758 39 payments
  6. Akebia Therapeutics Inc $732 42 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $719 38 payments
  8. Calliditas Therapeutics US Inc. $629 32 payments
  9. AstraZeneca Pharmaceuticals LP $621 32 payments
  10. Mallinckrodt Hospital Products Inc. $616 28 payments
  11. Other $3,972 202 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,830 636 payments
  2. Education $40 5 payments
Products named General payments · program years 2019–2025
  1. JYNARQUE $928 43 payments
  2. Ozempic $791 47 payments
  3. Kerendia $719 38 payments
  4. Veltassa $648 34 payments
  5. TARPEYO $504 27 payments
  6. Auryxia $494 31 payments
  7. Velphoro $491 27 payments
  8. ACTHAR $461 21 payments
  9. RAYALDEE $440 24 payments
  10. FARXIGA $412 20 payments
  11. Other $4,999 251 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 73 drugs

Part D claims

4,334

Median for Nephrology: 954

Drug cost

$450,603

Median for Nephrology: $127,050

Branded share of claims

19.6%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Procrit Epoetin Alfa Brand 94 $63,432
Farxiga Dapagliflozin Propanediol Brand 61 $54,604
Ozempic Semaglutide Brand 40 $48,790
Lokelma Sodium Zirconium Cyclosilicate Brand 33 $35,966
Velphoro Sucroferric Oxyhydroxide Brand 11 $32,829
Eliquis Apixaban Brand 22 $25,753
Januvia Sitagliptin Phosphate Brand 15 $22,644
Linzess Linaclotide Brand 22 $17,804
Sevelamer Carbonate Generic 68 $15,629
Veltassa Patiromer Calcium Sorbitex Brand 12 $13,938

The 10 drugs with the highest cost, of 73 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$278,515

Of which drugs: $1,218

Medicare patients

484

Average age 75

Services billed

2,180

245 women, 239 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 70%
Heart failure 49%
Ischemic heart disease 40%
Arthritis 40%
Atrial fibrillation 31%
Depression 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 14 14 $1,145

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$242 — —
JYNARQUE
$226 — —
TARPEYO
$168 — —
IBSRELA
$156 — —
Veltassa
$148 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

641 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record